透析患者高钾血症的当前管理
本综述聚焦维持性透析的终末期肾病患者高钾血症管理,指出透析、饮食限钾和避免升钾药物是关键手段,并探讨新型钾结合剂帕替罗姆和环硅酸锆钠的潜在非透析选择,可能减少严格饮食限制及其对营养状况的影响。
要点
- 透析患者高钾血症风险高,尤其血透患者。
- 关键管理包括透析、限钾饮食和避免升钾药物。
- 新型钾结合剂可能减少严格饮食限制及高钾风险。
核心结论
- 透析患者高钾血症管理需综合透析、饮食和药物调整,新型钾结合剂提供非透析选择。
研究设计与样本
- 综述,通过示例病例展示维持性透析患者高钾血症管理的问题与挑战。
主要发现
- 维持性血透患者高钾血症风险高。
- 新型钾结合剂帕替罗姆和环硅酸锆钠可能减少严格饮食限制及其对营养状况的影响。
关键数值与推荐
- 高钾血症通常定义为血清钾浓度>5.0 mmol/l。
临床怎么用
- 对维持性透析患者应评估高钾风险,综合透析、饮食和药物管理。
- 可考虑新型钾结合剂以减少饮食限制并降低高钾风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with end-stage renal disease (ESRD) on maintenance dialysis have a high risk of developing hyperkalemia, generally defined as serum potassium (K+) concentrations of >5.0 mmol/l, particularly those undergoing maintenance hemodialysis. Currently, the key approaches to the management of hyperkalemia in patients with ESRD are dialysis, dietary K+ restriction, and avoidance of medications that increase hyperkalemia risk. In this review, we highlight the issues and challenges associated with effective management of hyperkalemia in patients undergoing maintenance dialysis using an illustrative case presentation. In addition, we examine the potential nondialysis options for the management of these patients, including use of the newer K+ binder agents patiromer and sodium zirconium cyclosilicate, which may reduce the need for the highly restrictive dialysis diet, with its own implication on nutritional status in patients with ESRD, as well as reducing the risk of potentially life-threatening hyperkalemia.
引用
- Bansal S, Pergola PE. Current Management of Hyperkalemia in Patients on Dialysis. Kidney Int Rep. 2020. PMID: 32518860. doi:10.1016/j.ekir.2020.02.1028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。